Dr. Reddy’s Laboratories Limited, along with its subsidiaries together on Tuesday announced the launch of authorized generic version of NitroDur (nitroglycerin) Transdermal Infusion System in the US Market.
The announcement was made today, BSE and NSE are shut today on account of Ambedkar Jayanti. Dr. Reddy’s Laboratories rose the combined market for all Nitrogylcerin Transdermal Patch products had U.S. sales of approximately $14.7 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health, a company statement here said.